Home : DrugWatch : Cubicin : Newsfeeds

Cubicin - Newsfeeds

The Boston Globe names Cubist to Globe 100's Top Places to Work '09 ...
Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist entered into an agreement with AstraZeneca to promote their established antibiotic, MERREM(R) I.
Cubist nearly doubles quarterly revenue in a year
The company’s antibiotic drug Cubicin (daptomycin for injection) brought in $109.2 million for the quarter, with the remaining net revenue of $1.4 million stemmed from Cubist’s exclusive agreement with AstraZeneca PLC (NYSE: AZN) to commercialize ...
Cubist Pharma Files Patent Infringement Lawsuit Against Teva - Update
Cubist markets daptomycin in the U.S. and global markets under the brand name Cubicin (daptomycin for injection) as therapy for serious skin and bloodstream infections caused by certain Gram-positive bacteria. Commenting on the development, Michael ...
Cubist files IP lawsuit against Teva
TPM is looking for approval of its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration for a generic version of daptomycin, sold as Cubicin (daptomycin for injection) by Cubist, before the Lexington biotech’s patent ...
Daptomycin in experimental murine pneumococcal meningitis
Daptomycin, a lipopeptide antibiotic, could be an alternative to vancomycin for treatment of pneumococcal meningitis. We determined the activity of daptomycin versus vancomycin, with dexamethasone as an adjuvant, in a murine model of pneumococcal ...
The cure no one saw
Several years ago, a small Cambridge biotechnology firm called Cubist Pharmaceuticals made a surprising business deal. It licensed the rights to a failed drug, called daptomycin. Though the novel antibiotic showed promise in treating serious ...
INSERTING and REPLACING Cubist Pharmaceuticals to Present at June 2009 ...
In the U.S., Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist began promoting MERREM(R) I.V. (meropenem for injection) in ...
Cubist Pharmaceuticals 2 nd Quarter Total Net Revenues Up 28%
These factors include the following: the level of acceptance of CUBICIN by physicians, patients, third-party payors and the medical community; any changes in the current or anticipated market demand or medical need for CUBICIN ...
3 Small-Cap Stocks the Pros Like
The Lexington, Mass., company's flagship product—Cubicin, an antibiotic that treats a bacterial skin infection called MRSA—enjoys patent protection until 2019. The $1.3 billion company, which reported sales of $250 million in 2007, recently ...
Cubist Pharmaceuticals Initiates Phase 2 Trial in Europe for Therapy ...
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc. AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies. Cubist Pharmaceuticals, Inc.Eileen C. McIntyre, 781-860-8533Senior Director, Corporate ...
Cubist Pharma Swings to a Profit
Cubist Pharmaceuticals ( CBST Quote ) swung to a second-quarter profit from a loss one year ago as sales of its antibiotic Cubicin met reduced Street expectations. More on CBST Options Recap: Deutsche Telekom, Cubist Cubist Could Be in Play, Options ...
UPDATE 1-Cubist Q2 profit tops Street
July 16 (Reuters) - Cubist Pharmaceuticals Inc ( CBST.O ) posted a quarterly profit that beat analysts' expectations, helped by a 27 percent jump in U.S. sales of Cubicin, its antibiotic injection to treat bacterial infections. For the second quarter ...
Cubist and Forma Therapeutics form a multi-million dollar deal
Cubist has invested in its methicillin-resistant Staphylococcus aureus (MRSA) treatment, Cubicin, for about a decade. In 1997, Cubist (Nasdaq: CBST) acquired rights to Cubicin from Eli Lilly & Co. and won FDA approval in 2003. Getting it to market ...
Analyst upgrades, downgrades and initiations: AXP, FCX, FIG, JPM, LYG ...
Oppenheimer downgraded Cubist Pharmaceuticals (NASDAQ: CBST) to Underperform from Perform on valuation as it sees low probability of a takeout and Cubicin litigation risk. Opco thinks shares are fairly valued in the $17-$19 range after adjusting for ...
Cubist Pharmaceuticals and the New England Patriots Radio Network Team ...
In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist entered into an agreement with AstraZeneca to promote their ...
Do you need a District of Columbia Cubicin lawyer? Contact one of our District of Columbia Cubicin lawyers now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Pages: Previous   1   2  

Need A Cubicin Attorney?

First Name Last Name Email Address State
Has Your Health Been Negatively Affected?

Please Describe the Injury

Your Friend's Email Address

Your Email Address

Type a Message (optional)


Do you need a District of Columbia Cubicin lawyer? Contact one of our District of Columbia Cubicin lawyers now.

 

Close (x)

Looking for an Attorney?


Please type your question:

Close (x)

logo Find Legal Help for Your Cubicin Case - Submit Your Information Below

Do you need legal assistance with your Cubicin case?
LegalView may be able to help.


Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *
Last name *
Email Address *
Phone Number *
()  -

State *
Legal Issue * DrugWatch: Cubicin Change
Was There an Injury?
Please Describe The Injury

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website [more...]

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.
This form is secure and encrypted. More information about secure forms and your privacy here.